Get started
Author

Benjamin Papoular

Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients
2015 · Michaela Semeraro, Sylvie Rusakiewicz, et al. · Science Translational Medicine · 153
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
2019 · Francine Garnache-Ottou, Chrystelle Vidal, et al. · Blood Advances · 122
PDF
MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491
2020 · Gabriel Levy, Serge Carillo, et al. · Blood · 19
Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial
2018 · Raphael Itzykson, Elise Fournier, et al. · Blood · 2
Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo
2025 · Pierre Peterlin, Mael Heiblig, et al. · Blood · 1
PDF
Ps1441 a Novel Activating Tpor Mutation in Essential Thrombocytopenia Points to an Activating Effect of Tryptophan and Aromatics at the Outset of the Transmembrane Domain
2019 · G. Levy, S. Carillo, et al. · HemaSphere · 1
A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML)
2018 · Valérie Vidal, Laila Hamri, et al. · Blood · 1
CD3xCD20 bispecific antibodies in transformed Waldenström macroglobulinemia/lymphoplasmacytic lymphoma
2026 · Morgane Brocard, Damien Roos‐Weil, et al. · HemaSphere
Ivosidenib in refractory or relapsed IDH1-mutated Acute Myeloid Leukemia patients in real life settings: The ivoobs observational study from the french AML intergroup ALFA/filo
2025 · Mael Heiblig, Pierre Peterlin, et al. · Blood
PDF
264 | Cd3xcd20 Bispecific Antibodies in Transformed Waldenström Macroglobulinemia/lymphoplasmacytic Lymphoma
2025 · M. Brocard, D. Roos‐Weil, et al. · Hematological Oncology
PDF
Works count: 10
Citation count: 299
H-index: 3
I10-index: 3
Year
Topic
Type